About tRNA wybutosine-synthesizing protein 5
tRNA wybutosine-synthesizing protein 5 (TYW5) is a protein
from Homo sapiens identified by UniProt accession
A2RUC4, 315 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | tRNA wybutosine-synthesizing protein 5 |
|---|
| UniProt accession | A2RUC4 |
|---|
| Gene | TYW5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 315 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (37)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.28
- Red cell distribution width · score 0.24
- body weight · score 0.18
- health study participation · score 0.17
- smoking status measurement · score 0.16
- bipolar disorder · score 0.14
- autism spectrum disorder · score 0.14
- attention deficit hyperactivity disorder · score 0.14
- anorexia nervosa · score 0.13
- ventricular tachycardia · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A2RUC4-F1 | alphafold | PREDICTED | 95.76 | — |
Amino-acid sequence (315 residues)
MAGQHLPVPR LEGVSREQFM QHLYPQRKPL VLEGIDLGPC TSKWTVDYLS QVGGKKEVKI HVAAVAQMDF ISKNFVYRTL PFDQLVQRAA EEKHKEFFVS EDEKYYLRSL GEDPRKDVAD IRKQFPLLKG DIKFPEFFKE EQFFSSVFRI SSPGLQLWTH YDVMDNLLIQ VTGKKRVVLF SPRDAQYLYL KGTKSEVLNI DNPDLAKYPL FSKARRYECS LEAGDVLFIP ALWFHNVISE EFGVGVNIFW KHLPSECYDK TDTYGNKDPT AASRAAQILD RALKTLAELP EEYRDFYARR MVLHIQDKAY SKNSE
Explore tRNA wybutosine-synthesizing protein 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets